Literature DB >> 14559101

New technologies in therapeutic antibody development.

O H Brekke1, G Å Løset.   

Abstract

The development of therapeutic antibodies took a sharp turn with the introduction of phage display technology over a decade ago. Antibodies are used in a whole range of disease fields, such as autoimmunity, cancer, inflammation and infectious diseases. Now, the first antibody derived from phage display technology has been approved in the US by the Food and Drug Administration. The antibody industry is continuously developing new and robust discovery platforms and novel antibody formats, which points to the versatility of antibodies as therapeutic and diagnostic agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559101     DOI: 10.1016/j.coph.2003.05.002

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  15 in total

1.  Highly efficient selection of epitope specific antibody through competitive yeast display library sorting.

Authors:  Vinita Puri; Emily Streaker; Ponraj Prabakaran; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  MAbs       Date:  2013-05-29       Impact factor: 5.857

2.  Toward chaperone-assisted crystallography: protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (VHH) scaffold.

Authors:  Valentina Tereshko; Serdar Uysal; Akiko Koide; Katrina Margalef; Shohei Koide; Anthony A Kossiakoff
Journal:  Protein Sci       Date:  2008-04-29       Impact factor: 6.725

3.  Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.

Authors:  Ian C Wilkinson; Susan B Fowler; Leeann Machiesky; Kenneth Miller; David B Hayes; Morshed Adib; Cheng Her; M Jack Borrok; Ping Tsui; Matthew Burrell; Dominic J Corkill; Susanne Witt; David C Lowe; Carl I Webster
Journal:  MAbs       Date:  2013-04-08       Impact factor: 5.857

4.  A critical evaluation of Tm(FTIR) measurements of high-concentration IgG1 antibody formulations as a formulation development tool.

Authors:  Susanne Matheus; Hanns-Christian Mahler; Wolfgang Friess
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

5.  Characterization of the native and denatured herceptin by enzyme linked immunosorbent assay and quartz crystal microbalance using a high-affinity single chain fragment variable recombinant antibody.

Authors:  Yuqin Shang; Ray Mernaugh; Xiangqun Zeng
Journal:  Anal Chem       Date:  2012-09-13       Impact factor: 6.986

6.  Uniform amplification of phage with different growth characteristics in individual compartments consisting of monodisperse droplets.

Authors:  Ratmir Derda; Sindy K Y Tang; George M Whitesides
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

7.  Immobilization of a human epidermal growth factor receptor 2 mimotope-derived synthetic peptide on Au and its potential application for detection of herceptin in human serum by quartz crystal microbalance.

Authors:  Yuqin Shang; Pankaj R Singh; Mohammad M Chisti; Ray Mernaugh; Xiangqun Zeng
Journal:  Anal Chem       Date:  2011-11-03       Impact factor: 6.986

Review 8.  Advances in the treatment of hematologic malignancies using immunoconjugates.

Authors:  Maria Corinna Palanca-Wessels; Oliver W Press
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113

9.  Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries.

Authors:  Barrett R Harvey; George Georgiou; Andrew Hayhurst; Ki Jun Jeong; Brent L Iverson; Geoffrey K Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

10.  Generating conformation-specific synthetic antibodies to trap proteins in selected functional states.

Authors:  Marcin Paduch; Akiko Koide; Serdar Uysal; Shahir S Rizk; Shohei Koide; Anthony A Kossiakoff
Journal:  Methods       Date:  2012-12-29       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.